Cargando…

The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors

Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characterist...

Descripción completa

Detalles Bibliográficos
Autores principales: Steens, Jurre A., Salazar, Carl Raymund P., Staals, Raymond H.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704534/
https://www.ncbi.nlm.nih.gov/pubmed/36282000
http://dx.doi.org/10.1042/BST20220289
_version_ 1784840075609112576
author Steens, Jurre A.
Salazar, Carl Raymund P.
Staals, Raymond H.J.
author_facet Steens, Jurre A.
Salazar, Carl Raymund P.
Staals, Raymond H.J.
author_sort Steens, Jurre A.
collection PubMed
description Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characteristic Cas10 subunit and sets in motion a variety of catalytic activities that starts with the production of cyclic oligoadenylate (cOA) second messenger molecules. These messenger molecules can activate an extensive arsenal of ancillary effector proteins carrying the appropriate sensory domain. Notably, the CARF and SAVED effector proteins have been responsible for renewed interest in type III CRISPR–Cas due to the extraordinary diversity of defenses against invading genetic elements. Whereas only a handful of CARF and SAVED proteins have been studied so far, many of them seem to provoke abortive infection, aimed to kill the host and provide population-wide immunity. A defining feature of these effector proteins is the variety of in silico-predicted catalytic domains they are fused to. In this mini-review, we discuss all currently characterized type III-associated CARF and SAVED effector proteins, highlight a few examples of predicted CARF and SAVED proteins with interesting predicted catalytic activities, and speculate how they could contribute to type III immunity.
format Online
Article
Text
id pubmed-9704534
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97045342022-12-06 The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors Steens, Jurre A. Salazar, Carl Raymund P. Staals, Raymond H.J. Biochem Soc Trans Review Articles Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characteristic Cas10 subunit and sets in motion a variety of catalytic activities that starts with the production of cyclic oligoadenylate (cOA) second messenger molecules. These messenger molecules can activate an extensive arsenal of ancillary effector proteins carrying the appropriate sensory domain. Notably, the CARF and SAVED effector proteins have been responsible for renewed interest in type III CRISPR–Cas due to the extraordinary diversity of defenses against invading genetic elements. Whereas only a handful of CARF and SAVED proteins have been studied so far, many of them seem to provoke abortive infection, aimed to kill the host and provide population-wide immunity. A defining feature of these effector proteins is the variety of in silico-predicted catalytic domains they are fused to. In this mini-review, we discuss all currently characterized type III-associated CARF and SAVED effector proteins, highlight a few examples of predicted CARF and SAVED proteins with interesting predicted catalytic activities, and speculate how they could contribute to type III immunity. Portland Press Ltd. 2022-10-31 2022-10-25 /pmc/articles/PMC9704534/ /pubmed/36282000 http://dx.doi.org/10.1042/BST20220289 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Articles
Steens, Jurre A.
Salazar, Carl Raymund P.
Staals, Raymond H.J.
The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title_full The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title_fullStr The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title_full_unstemmed The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title_short The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
title_sort diverse arsenal of type iii crispr–cas-associated carf and saved effectors
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704534/
https://www.ncbi.nlm.nih.gov/pubmed/36282000
http://dx.doi.org/10.1042/BST20220289
work_keys_str_mv AT steensjurrea thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors
AT salazarcarlraymundp thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors
AT staalsraymondhj thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors
AT steensjurrea diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors
AT salazarcarlraymundp diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors
AT staalsraymondhj diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors